- Accession Number:
- Form Type:
- Zero Holdings:
- Publication Time:
- 2014-12-22 20:07:34
- Reporting Period:
- Filing Date:
- Accepted Time:
- 2014-12-22 20:07:34
- SEC Url:
- Form 4 Filing
|Cik||Name||Symbol||Sector (SIC)||IRS No|
|858803||Avanir Pharmaceuticals Inc.||AVNR||Pharmaceutical Preparations (2834)||330314804|
|Cik||Name||Reported Address||Insider Title||Director||Officer||Large Shareholder||Other|
|1534986||Md Joao Siffert||30 Enterprise |
Aliso Viejo CA 92656
Reported Non-Derivative Transactions
|Sec. Name||Acquisiton - Disposition||Date||Amount||Price||Remaning Holdings||Equity Swap Involved||Form Type||Code||Nature of Ownership||Explanation|
|Equity Swap Involved||Form Type||Code||Nature of Ownership||Explanation|
Reported Derivative Transactions
|Sec. Name||Sec. Type||Acquisiton - Disposition||Date||Amount||Price||Amount - 2||Price - 2|
|Common Stock||Stock Option (right to buy)||Disposition||2014-12-18||32,291||$0.00||32,291||$2.59|
|Remaning Holdings||Exercise Date||Expiration Date||Equity Swap Involved||Transaction Form Type||Transaction Code||Nature of Ownership|
- Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting Person, which are subject to certain vesting conditions.
- The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. A majority of the proceeds from the sales will be used to pay required withholdings due by the Reporting Person for vesting RSUs.
- Represents the weighted-average price at which shares were sold within a range between $16.93 and $16.94. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
- The option was granted on 12/17/2012 and vested with respect to one-quarter of the underlying shares upon the first anniversary of the grant date, and then with respect to the remaining shares quarterly thereafter over the next three years.